Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
In spite of some exceptions, the clinical microbiology lab has been a late starter as far as automation is concerned. It has also traditionally been viewed as ‘low tech’, especially when compared to its cousins in clinical chemistry or pathology. A variety of factors, however, have been converging to reverse such a situation.
Automation hampered by process complexity
One of the most important barriers to the automation of a clinical microbiology lab is process complexity. Unlike hematology or chemistry labs, which have little diversity in specimens and generally use standard collection tubes, microbiology laboratories need to work with a vast range of specimen types in a multitude of transport containers. The complex nature of specimen processing and culturing and the ensuing lack of standardization have been major deterrents to automation.
Nevertheless, growth in the presence of automated technologies in clinical microbiology labs is now expected to accelerate as a result of several factors, above all rising demand. This requires agility and high responsiveness, making automation indispensable.
Ageing populations drive demand
Ageing populations with more-complex diseases and conditions require a growing number of tests – for example, to monitor implants and prosthetic devices for infections. The elderly also need greater care in medicating, since they are more prone to adverse drug events.
In the year 2000, an article by Dr. Thomas T. Yoshikawa of the King-Drew Medical Center in Los Angeles noted that though “the major focus in infectious diseases for the past decade has been on young adults”, in the future “the vast majority of serious infectious diseases will be seen in the elderly population.”
Infectious disease, resistant bacteria
The rise in infectious disease outbreaks in recent decades is another factor driving demand for early detection by clinical microbiology labs, to contain their spread.
On their part, multidrug-resistant pathogens pose their own specific challenges. Delays in obtaining lab results leads to over-treatment of many patients – and increased antibiotic resistance. In 2008, a team from Erasmus University Medical Centre in Rotterdam found that quicker microbiological lab turnaround led to “a significant reduction in antibiotic use” in a study of almost 1,500 patients. This finding assumes considerable significance when one takes account of the fact that 5 years later, another study found that just 3% of community-acquired respiratory infections in the UK were guided by laboratory results.
The role of budgets and cutbacks
In an era of budgetary cutbacks, financial considerations too have reinforced demands for the automation of clinical microbiology labs. There is some irony here. Given the nature of a hospital business, it has been easier for administrators to assess the productivity of their clinical laboratories, determine return on investment (RoI) and justify new outlays – via quantifying and benchmark tests and staff numbers. Such an exercise has, in general, already been conducted for other hospital labs. It is now the clinical microbiology laboratory’s turn.
The above considerations are summed up in an article in the December 2013 issue of the journal ‘Clinical Chemistry’ which quotes Gilbert Greub of the Institute of Microbiology at the University Hospital in Lausanne, Switzerland. He says that the key reasons for the Hospital’s decision to move toward a fully automated laboratory consisted of a shortage of financial resources and the concomitant increase in activity of the Hospital’s clinical diagnostic microbiology laboratory “of about 4% to 12% per year.”
Workflow improvement, staff shortages
Indeed, improvements in workflow and quicker test results are also directly related to growing automation. One of the most important collateral effects of this is the freeing up of staff for other work.
In May 2009, the ‘Wall Street Journal’ warned about “the shrinking ranks of skilled lab workers” in the US, which pose “a potential threat to the safety and quality of health care”. Hospitals, it continued, said that “it can take as much as a year to fill some job openings,” while an American Society for Clinical Pathology (ASCP) survey found average job-vacancy rates topping 50% in some states.
The ASCP survey also illustrated another interesting fact. Laboratories which were affected by new technologies found a decreased need for as large a staff. However, 75% of respondents said they were not affected by new technologies. In other words, not only does automation seem to be an answer to staff shortages. There is also a lot of untapped room for growth.
Europe faces staff shortages too. A report by Belgium’s University Hospital at Leuven highlights the challenges of an ageing workforce, alongside major waves of retirement which have started recently and are expected to continue for several years. The problem is exacerbated by a decline in interest in labs as a career and the presence in the workforce of fewer young recruits. As a result, the paper warns, there is a “trend towards employing less-trained technicians.”
Transferring skills to points of need
The benefit of automation in the face of labour shortages is to utilize the skills of medical laboratory professionals where they are most needed and to automate tasks that are repetitive and do not require the comprehensive skill set of a trained professional.
For example, a laboratory could use an automated system for mundane and repetitive tasks such as “planting and streaking of urine samples and other liquid specimens,” while assigning a lab technician “to perform Gram stain review and processing of more-complex specimens, such as tissue.”
At the other end, boredom can also be a problem. In a non-automated environment, lab staff frequently complain of poor turnaround (TAT), referring to the duration or idling time between inoculation of media and microbial growth. By shifting monotonous tasks to automation, while assigning higher-skill tasks to a technologist, the laboratory reduces boredom and increases productivity.
The May 2009 article by the ‘Wall Street Journal’ quotes Dr. Carol Wells, director of the clinical laboratory sciences programme at the University of Minnesota in Minneapolis: “Many tests are automated, but that doesn’t mean a lab monkey can do them.” The machines, she continues, need careful monitoring. Should they “spit out a result” which does not make sense, only a skilled lab technician can catch a possible discrepancy and determine what is wrong.
Liquid-based microbiology, MALDI-TOF mass spectrometry drive demand
Automation of the clinical microbiology lab is also being driven by supply-side factors.
Among the first is the advent of new technologies, such as liquid-based microbiology and mass spectrometry. Liquid-based microbiology allows specimens of varying viscosities (e.g. stool or sputum) to be homogenized into a liquid phase, in order to enable greater consistency in the inoculation of medium. Specimen elution from recent flocked-style swabs into liquid phase has also resulted in a significant increase in the release of viable organisms from the swab, in other words resulting in greater sensitivity for detection of microorganisms.
The second technology is matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry. This permits the accurate and rapid identification of microorganisms isolated from clinical specimens. MALDI-TOF procedures “are highly amenable to automation because they are relatively simple, do not change based on organism, and are reproducible.” In addition, target plate spotting and extraction of proteins “can be standardized for most organisms, and when combined with automation, automated crude extraction using the on-plate formic acid extraction method can be performed with minimal staffing.”
Specimen processing as entry point
One of the first points of entry by new technology in a clinical microbiology lab consists of front-end instrumentation to automate and standardize initial specimen processing. Automation of the front-end makes it possible for tests to be conducted as soon as specimens arrive, obviating the need for a separate ‘stat’ lab.
Nevertheless, the impact of automation in specimen processing is not necessarily uniform, and depends on the needs of a particular laboratory. One study by researchers at Penn State College of Medicine and Medical College of Wisconsin estimated break-even point of more than 4 years for a barcode-driven, conveyor-connected automated specimen processing system which included plating and streaking, incubation, image acquisition, and digital microbiology.
Full- versus partial automation
As with other types of clinical labs, automation of the clinical microbiology laboratory can be classified into total (or full) laboratory automation or modular automation. Most automation systems have traditionally been designed for the larger, high-volume laboratory with substantial specimen throughput requirements. More recently, automated processing units have been designed for the pre-analytical section of smaller/medium-sized laboratories.
In effect, smaller labs can choose to automate only some of the processing steps. The investment required for automation makes such a choice imperative. The report by the University Hospital at Leuven cited previously notes that its own implementation of ‘full lab automation’ cost €3.2 million with €1.7 million in capital investment and another €1.5 million for refurbishment. Time needs to be also factored in. The Leuven study notes that their automation entailed 1 year in preparatory work and 1 year for adaptation. Against this, the savings achieved were equivalent to 3.8 full time employees (FTE).
Some hospitals begin small and scale up. For example, the University Hospital in Lausanne, Switzerland, started with two stand-alone automated systems for microbial identification. It moved after a few years “to a fully automated laboratory, by adding the missing pieces to the puzzle, i.e., smart incubators, high-quality digital imaging, an automated colony-picking system, and all required transport belts in between.”
A glimpse of the future
Today, state-of-the-art clinical microbiology labs have the potential to automate nearly all areas of testing, including inoculation of primary culture plates, detection of growth on culture media, identification of microorganisms, susceptibility testing, and extraction and detection of nucleic acids in clinical samples. In the future, process standardization is expected to be reinforced by high-resolution digital imaging and robotics, and take automation in the clinical microbiology lab to wholly new frontiers.
The aim of the first annual World Antibiotic Awareness Week, held in November, was to raise recognition of the growing problem of bacterial resistance to antimicrobials and to disseminate information on how these drugs can be used more prudently. Is it still possible, though, to prevent an antibiotic apocalypse?
The development of drug-resistant bacteria is the inevitable result of natural selection, but formerly the discovery of novel compounds kept pace with microbial evolution; this is no longer the case. During the past decade numerous academic articles have reported alarming examples of antibiotic resistance in microorganisms, including multidrug-resistant Staphylococcus aureus and Mycobacterium tuberculosis, as well as extensively drug-resistant tuberculosis, and the mass media has duly disseminated this information to the general public. Around 5 years ago the NDM-1 gene, which confers resistance to the potent carbapenem antibiotics used against multi-resistant strains of Gram-negative bacilli, was found in Enterobacteriaceae including the ubiquitous Escherichia coli. The latest catastrophe is the emergence of the MCR-1 mechanism that allows polymixin-resistance plasmids to be transferred between strains of Enterobacteriaceae. And polymixins are (or should be) the drugs of last resort to treat infections with bacteria that are multidrug resistant, including carbapenem-resistant strains.
As well as over-liberal medical prescription of unnecessary antibiotics without prior diagnostic testing, premature cessation of treatment and unregulated sources of drugs enabling “self-prescription”, the routine use of antimicrobials in industrialized agriculture has greatly exacerbated the resistance problem. The recently reported polymixin resistance was first observed in China during routine testing of commensal E. coli in food animals, prompting a robust study that discovered the MCR-1 mechanism in 15% of E. coli isolates from raw meat, 21% of isolates from livestock and 1% of isolates from infected patients. Although the problem is currently confined to China, this type of mechanism spreads resistance so easily between bacteria that it will soon become a global problem. Should polymixin-resistance plasmids be transferred to Enterobacteriaceae that are already multidrug-resistant, truly untreatable Gram-negative bacterial infections would result.
Initiatives to prevent the further squandering of antibiotics coupled with rigorous infection control procedures are highly unlikely to prevent an antibiotic apocalypse now. But a worldwide ban on the veterinary use of medical antimicrobials might just stem the tide until new drugs (such as teixobactin for multidrug-resistant Gram-positive pathogens) have been approved.
November 2024
The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy